References
McDougle CJ, Scahill L, Aman MG, et al.: Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005, 162: 1142–1148.
Chavez B, Chavez-Brown M, Rey JA: Role of risperidone in children with autism spectrum disorder. Ann Pharmacother 2006, 40: 909–916.
Kolevzon A, Mathewson KA, Hollander E: Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry 2006, 67: 407–414.
Posey DJ, Erickson CA, Stigler KA, McDougle CJ: The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 2006, 16: 181–186.
Carter AS, Volkmar FR, Sparrow SS, et al.: The Vineland Adaptive Behavior Scales: supplementary norms for individuals with autism. J Autism Dev Disorder 1998, 28: 287–302.
Sutcliffe JS, Delahanty RJ, Prasad HC, et al.: Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 2005, 77: 265–279.
Campbell DB, Sutcliffe JS, Ebert PJ, et al.: A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A 2006, 103: 16834–16839.
Wexler BE, Bell MD: Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull 2005, 31: 931–941.
Rights and permissions
About this article
Cite this article
Cubells, J.F. Clinical trials report. Curr Psychiatry Rep 9, 131–134 (2007). https://doi.org/10.1007/s11920-007-0082-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-007-0082-y